Rx License-Rx

KIR03-04

Gene-signature for Predicting Immune-Related Adverse Events (irAEs) After Immune Checkpoint Inhibitor (ICI) Treatment

A novel predictive biomarker to guide personalized immune checkpoint treatments after surgical removal of melanoma.

Intelligence Memo

Owner: University-originated technology office

Core category: Medical Devices

Therapeutic area: Oncology

Indication:

Modality: Small Molecule

Focus tags: Oncology, Immunology

Technology tags: Small Molecule, Diagnostic / Biomarker

Mechanism:

Development stage: Early / Discovery

Patent status: Needs review

Availability: Available for license

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Merck — Checkpoint-franchise adjacency and combination-trial appetite. AstraZeneca — Oncology breadth plus interest in biomarker-defined populations. Roche / Genentech — Diagnostics plus oncology translational machinery.

Development Strategy to Increase PoS

First indication: a molecularly selected tumor segment where a small proof-of-mechanism study is credible

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform

Best next experiment: Run the smallest independent study that validates: Run a usability + analytical validation package first, then pursue a small prospective study at one high-volume clinical site.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.